Ewha Womans University 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
41 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
prexasertib (ACR-368) / Acrivon Therap
ExIST, NCT04032080: LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

Completed
2
10
US
Drug 1: LY3023414; Drug 2: Prexasertib
Baylor Research Institute, Eli Lilly and Company
Triple Negative Breast Cancer
06/22
11/22
NCT06597565: A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Recruiting
2
43
US
Gemcitabine, ACR-368, Prexasertib
H. Lee Moffitt Cancer Center and Research Institute, Acrivon Therapeutics
Head and Neck Squamous Cell Carcinoma
08/28
08/28
NCT04095221: A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Completed
1/2
21
US
Prexasertib, Irinotecan
Memorial Sloan Kettering Cancer Center
Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma
02/25
02/25
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
St. Jude ELIOT, NCT04023669: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Completed
1
21
US
Prexasertib, LY2606368, Cyclophosphamide, Cytoxan, Gemcitabine, 2'-deoxy-2',2' difluorocytidine monohydrochloride, LY18801, Gemzar®, filgrastim, G-CSF, peg-filgrastim, pegylated filgrastim, PEG filgrastim, Neulasta®
St. Jude Children's Research Hospital, Eli Lilly and Company
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
05/23
01/25
Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
TheraCRAB, NCT06440304: Therapeutic Options for CRAB

Recruiting
4
108
RoW
Fosfomycin, Fosfomycin with Colistin, Eravacycline, Eravacycline with Colistin, ampicillin/sulbactam, Ampicilin/sulbactam with Colistin
Clinical Hospital Centre Zagreb
Infections, Bacterial, Sepsis Bacterial
12/26
02/27
TREAT-GNB, NCT07004049: Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting
4
600
Europe, RoW
Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem, Ceftazidime-avibactam + Sulbactam, Ceftazidime-avibactam + Fosfomycin, Ceftazidime-avibactam, Ceftazidime-avibactam + Aztreonam, Ceftazidime-avibactam + Colistin/Polymyxin B, High-dose meropenem, Meropenem + Fosfomycin, Meropenem-vaborbactam, Cefiderocol, Ceftolozane-tazobactam, Ceftolozane-tazobactam + Meropenem
National University of Singapore, The University of Queensland, European Clinical Research Alliance for Infectious Diseases (ECRAID)
Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection, Multidrug Resistance
12/28
12/28
ChiCTR2400087137: A study on the pharmacokinetic characteristics and penetration of Eravacycline in the pulmonary bronchial fluid of adult patients with hospital-acquired pneumonia or ventilator-associated pneumonia

Not yet recruiting
4
16
 
Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Funded by Everest Medicines for this IIT study
HAP or VAP
 
 
ChiCTR2500098643: An exploratory study on the efficacy of eravacycline in CRKP infection

Not yet recruiting
4
60
 
Elacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazobactam, piperac; Tigacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazo
Shanghai tenth People's Hospital; Shanghai tenth People's Hospital, Self-funded project
Intraperitoneal infection, bloodstream infection, pulmonary infection, urinary infection
 
 
ChiCTR1900022060: A Phase 3, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Ertapenem in the Treatment of Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Adults

Completed
3
160
 
Eravacycline 1.0 mg/kg IV q 12h ;Ertapenem 1g IV q 24h
West China Hospital, Sichuan University; Everest Medicines (US) Limited, Fully founded by sponsor
Complicated intra-abdominal infections
 
 
ChiCTR2300078646: Efficacy and safety of eravacycline for complicated intra-abdominal infections in the ICU: A multicenter, single-blind, parallel randomized controlled trial study

Recruiting
3
292
 
Intravenous eravacycline; Intravenous tigecycline
Ansteel Group General Hospital; Ansteel Group General Hospital, Health Development Promotion Project of Beijing Health Alliance Charitable Foundation
Complicated intra-abdominal infections
 
 
ChiCTR2200055666: A Phase II/III, Randomized, Two-stage Clinical Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Moxifloxacin in the Treatment of Community-acquired Bacterial Pneumonia (CABP) in Adult Subjects

Recruiting
2/3
520
 
Elacycline 1.0 mg/kg IV q 12 h ;Two doses of eracycline 1.5 mg/kg IV were administered 12 hours apart (q12h). From the second day to the end of treatment (the third dose to the final dose), elacycline was 1.5 mg/kg, q24h ;Elacycline (dose and frequency determined in Stage 1) ;Moxifloxacin 0.4 g IV q24h
China-Japan Friendship Hospital; Everest Medicines (US) Limited, self-funded
Community-acquired Bacterial Pneumonia
 
 
NCT06794541: A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Recruiting
2
35
US
Eravacycline 2mg/kg, Eravacycline 1.5mg/kg
Innoviva Specialty Therapeutics, Tetraphase Pharmaceuticals, Inc.
Complicated Intra-abdominal Infections (cIAI)
03/29
03/29
NCT05537896: Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting
2
55
US
Eravacycline, Xerava
West Virginia University
Hematological Malignancy, Neutropenia
02/28
02/28
ChiCTR1900022906: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose and Multiple-dose Intravenous Infusion of Eraracycline in Chinese Healthy Subjects

Completed
1
28
 
Eravacycline 0.5 mg/kg IV single dose ;Single dose: Eravacycline 1 mg/kg IV; Multiple dose: Eravacycline 1 mg/kg IV q12h, 10 days ;Eravacycline 2 mg/kg IV single dose
Huashan Hospital Affiliated to Fudan University; Everest Medicines (US) Limited, Fully founded by sponsor
Not applicable
 
 
NCT06282835: Eravacycline Combination Therapy for MRAB

Recruiting
N/A
20
RoW
Eravacycline Injection
Fujian Medical University Union Hospital
Pulmonary Infection, Pneumonia, Bacterial, Acinetobacter Baumannii
10/24
12/24
NCT06223100: Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

Not yet recruiting
N/A
100
NA
Eravacycline, XERAVA
Sichuan Provincial People's Hospital
Immune Dysregulation Disorder
12/25
12/25
NCT06670872: A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia

Not yet recruiting
N/A
50
RoW
Eravacycline combination therapy group
Peking University Third Hospital
Pneumonitis, Acinetobacter Baumannii
10/25
10/26
NCT06666998: Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients

Not yet recruiting
N/A
100
NA
Sichuan Provincial People's Hospital
Eravacycline, Pharmacokinetics, Bacteria Infection, Bacterial Resistance to Antimicrobial, Empirical Antimicrobial Therapy
11/26
11/26
ChiCTR2400089338: The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data

Not yet recruiting
N/A
200
 
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Life Oasis Public Service Center
Granulocyte deficiency with fever
 
 
ChiCTR2400083038: A real-world study of the clinical use of eravacycline

Recruiting
N/A
50
 
None
Huashan hospital; Huashan hospital, Beijing Life Oasis public Service Center
Bacterial Infection
 
 
ChiCTR2500103344: Retrospective Study on the Efficacy and Safety of Eravacycline Based on Real-world Data

Not yet recruiting
N/A
300
 
NA
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, None
Patients clinically diagnosed with infections (including pulmonary infections, skin/soft tissue infections, intra-abdominal infections, bloodstream infections, etc.).
 
 
ChiCTR2500096976: Synergistic Mechanisms of Eravacycline Combined with Aminoglycosides in the Treatment of CRE Infections: A Single-Arm Clinical Study and Integrated Multi-Omics Analysis

Not yet recruiting
N/A
9
 
SUN YAT-SEN MEMORIAL HOSPITAL; SUN YAT-SEN MEMORIAL HOSPITAL, Primary Health Care Foundation of China
CRE infection
 
 
vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
NCT04656002: As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Not yet recruiting
2a
43
NA
Vactosertib, TEW-7197
Samsung Medical Center
Gastric Cancer
12/23
12/24
MP-VAC-206, NCT06219733: Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

Withdrawn
2
76
RoW
Vactosertib, Imatinib
MedPacto, Inc.
Dermoid
05/22
05/22
MP-VAC-205, NCT04515979: Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Terminated
2
11
RoW
Vactosertib 300 mg BID and pembrolizumab 200 mg IV, Vactosertib 300 mg BID and keytruda 200 mg IV
MedPacto, Inc.
Carcinoma, Non-Small-Cell Lung
08/24
08/24
NCT04103645: Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

Terminated
2
2
US
Vactosertib, TEW-7197
Weill Medical College of Cornell University
Myeloproliferative Neoplasm
07/24
07/24
NCT04064190: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Withdrawn
2
48
US
Vactosertib(TEW-7197)/ Durvalumab
MedPacto, Inc., AstraZeneca
Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
12/23
12/24
NCT04893252: Vactosertib and Durvalumab in Gastric Cancer

Recruiting
2
55
RoW
durvalumab and vactosertib
Hark Kyun Kim
Stomach Neoplasm
12/23
12/23
NCT03844750: Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Active, not recruiting
2
6
US
Hepatectomy, Liver Resection, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Vactosertib, EW-7197
Chloe Atreya, MD, PhD, Merck Sharp & Dohme LLC, MedPacto, Inc.
Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
04/26
04/26
NCT05436990: Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

Terminated
2
14
RoW
Pembrolizumab, Vactosertib
Yonsei University
Acral Melanoma, Mucosal Melanoma
03/25
03/25
NCT06044311: Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Recruiting
2
25
US
Vactosertib, Oral TGF-beta Receptor I Inhibitor, Standard of Care Chemotherapy, Carboplatin, Paciltaxel, Concurrent Radiation
Sakti Chakrabarti
Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
12/26
06/27
KEYNOTE 900, NCT03724851: Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer

Completed
1/2
120
RoW
TEW-7197, vactosertib
MedPacto, Inc., Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT03698825: TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer

Completed
1/2
62
RoW
TEW-7197, vactosertib
MedPacto, Inc.
Metastatic Gastric Cancer
01/22
12/22
MP-VAC-203, NCT03732274: Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

Completed
1/2
60
RoW
TEW-7197, vactosetib
MedPacto, Inc., AstraZeneca
Non-Small Cell Lung Cancer Metastatic
05/24
05/24
NCT03802084: A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor

Completed
1/2
24
RoW
vactosertib/imatinib combination
Hyo Song Kim
Desmoid Tumor
03/24
03/24
NCT05588648: Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Recruiting
1/2
48
US, RoW
Vactosertib, TEW-7197
MedPacto, Inc.
Osteosarcoma
09/25
12/25
MP-PDAC-01, NCT03666832: Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel

Recruiting
1b
36
RoW
TEW-7197, TEW-7197, FOLFOX
Joon Oh Park
Metastatic Pancreatic Cancer
12/22
12/23
NCT04258072: Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.

Recruiting
1b
24
RoW
Vactosertib, TEW-7197
Samsung Medical Center
Pancreas Cancer
12/22
03/23
CASE1A17, NCT03143985: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Completed
1
18
US
Vactosertib, TEW-7197, EW7197, EW-7197, Pomalidomide, POM
Koen van Besien
Multiple Myeloma
02/22
09/22
NCT05400122: Natural Killer (NK) Cells in Combination with Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Recruiting
1
12
US
Vactosertib, TEW-7197, EW-7197, EW7197, Fludarabine Phosphate, Fludara, Cyclophosphamide, Cytoxan, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, IL-2, Proleukin, Natural Killer Cells
David Wald
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
12/25
06/26
cynarine / Ewha Womans University, SOM Biotech
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
prexasertib (ACR-368) / Acrivon Therap
ExIST, NCT04032080: LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

Completed
2
10
US
Drug 1: LY3023414; Drug 2: Prexasertib
Baylor Research Institute, Eli Lilly and Company
Triple Negative Breast Cancer
06/22
11/22
NCT06597565: A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Recruiting
2
43
US
Gemcitabine, ACR-368, Prexasertib
H. Lee Moffitt Cancer Center and Research Institute, Acrivon Therapeutics
Head and Neck Squamous Cell Carcinoma
08/28
08/28
NCT04095221: A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Completed
1/2
21
US
Prexasertib, Irinotecan
Memorial Sloan Kettering Cancer Center
Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma
02/25
02/25
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
St. Jude ELIOT, NCT04023669: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Completed
1
21
US
Prexasertib, LY2606368, Cyclophosphamide, Cytoxan, Gemcitabine, 2'-deoxy-2',2' difluorocytidine monohydrochloride, LY18801, Gemzar®, filgrastim, G-CSF, peg-filgrastim, pegylated filgrastim, PEG filgrastim, Neulasta®
St. Jude Children's Research Hospital, Eli Lilly and Company
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
05/23
01/25
Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
TheraCRAB, NCT06440304: Therapeutic Options for CRAB

Recruiting
4
108
RoW
Fosfomycin, Fosfomycin with Colistin, Eravacycline, Eravacycline with Colistin, ampicillin/sulbactam, Ampicilin/sulbactam with Colistin
Clinical Hospital Centre Zagreb
Infections, Bacterial, Sepsis Bacterial
12/26
02/27
TREAT-GNB, NCT07004049: Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting
4
600
Europe, RoW
Colistin/Polymyxin B + Sulbactam, Colistin/Polymyxin B + Tigecycline/Eravacycline, Colistin/Polymyxin B + Meropenem, Ceftazidime-avibactam + Sulbactam, Ceftazidime-avibactam + Fosfomycin, Ceftazidime-avibactam, Ceftazidime-avibactam + Aztreonam, Ceftazidime-avibactam + Colistin/Polymyxin B, High-dose meropenem, Meropenem + Fosfomycin, Meropenem-vaborbactam, Cefiderocol, Ceftolozane-tazobactam, Ceftolozane-tazobactam + Meropenem
National University of Singapore, The University of Queensland, European Clinical Research Alliance for Infectious Diseases (ECRAID)
Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection, Multidrug Resistance
12/28
12/28
ChiCTR2400087137: A study on the pharmacokinetic characteristics and penetration of Eravacycline in the pulmonary bronchial fluid of adult patients with hospital-acquired pneumonia or ventilator-associated pneumonia

Not yet recruiting
4
16
 
Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection; Eravacycline Hydrochloride for Injection
Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Funded by Everest Medicines for this IIT study
HAP or VAP
 
 
ChiCTR2500098643: An exploratory study on the efficacy of eravacycline in CRKP infection

Not yet recruiting
4
60
 
Elacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazobactam, piperac; Tigacycline combine with other commonly used clinical fungicides (such as meropenem, polycolistin E, polymyxin B, levofloxacin, ceftazo
Shanghai tenth People's Hospital; Shanghai tenth People's Hospital, Self-funded project
Intraperitoneal infection, bloodstream infection, pulmonary infection, urinary infection
 
 
ChiCTR1900022060: A Phase 3, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Ertapenem in the Treatment of Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Adults

Completed
3
160
 
Eravacycline 1.0 mg/kg IV q 12h ;Ertapenem 1g IV q 24h
West China Hospital, Sichuan University; Everest Medicines (US) Limited, Fully founded by sponsor
Complicated intra-abdominal infections
 
 
ChiCTR2300078646: Efficacy and safety of eravacycline for complicated intra-abdominal infections in the ICU: A multicenter, single-blind, parallel randomized controlled trial study

Recruiting
3
292
 
Intravenous eravacycline; Intravenous tigecycline
Ansteel Group General Hospital; Ansteel Group General Hospital, Health Development Promotion Project of Beijing Health Alliance Charitable Foundation
Complicated intra-abdominal infections
 
 
ChiCTR2200055666: A Phase II/III, Randomized, Two-stage Clinical Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Moxifloxacin in the Treatment of Community-acquired Bacterial Pneumonia (CABP) in Adult Subjects

Recruiting
2/3
520
 
Elacycline 1.0 mg/kg IV q 12 h ;Two doses of eracycline 1.5 mg/kg IV were administered 12 hours apart (q12h). From the second day to the end of treatment (the third dose to the final dose), elacycline was 1.5 mg/kg, q24h ;Elacycline (dose and frequency determined in Stage 1) ;Moxifloxacin 0.4 g IV q24h
China-Japan Friendship Hospital; Everest Medicines (US) Limited, self-funded
Community-acquired Bacterial Pneumonia
 
 
NCT06794541: A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

Recruiting
2
35
US
Eravacycline 2mg/kg, Eravacycline 1.5mg/kg
Innoviva Specialty Therapeutics, Tetraphase Pharmaceuticals, Inc.
Complicated Intra-abdominal Infections (cIAI)
03/29
03/29
NCT05537896: Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting
2
55
US
Eravacycline, Xerava
West Virginia University
Hematological Malignancy, Neutropenia
02/28
02/28
ChiCTR1900022906: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose and Multiple-dose Intravenous Infusion of Eraracycline in Chinese Healthy Subjects

Completed
1
28
 
Eravacycline 0.5 mg/kg IV single dose ;Single dose: Eravacycline 1 mg/kg IV; Multiple dose: Eravacycline 1 mg/kg IV q12h, 10 days ;Eravacycline 2 mg/kg IV single dose
Huashan Hospital Affiliated to Fudan University; Everest Medicines (US) Limited, Fully founded by sponsor
Not applicable
 
 
NCT06282835: Eravacycline Combination Therapy for MRAB

Recruiting
N/A
20
RoW
Eravacycline Injection
Fujian Medical University Union Hospital
Pulmonary Infection, Pneumonia, Bacterial, Acinetobacter Baumannii
10/24
12/24
NCT06223100: Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

Not yet recruiting
N/A
100
NA
Eravacycline, XERAVA
Sichuan Provincial People's Hospital
Immune Dysregulation Disorder
12/25
12/25
NCT06670872: A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia

Not yet recruiting
N/A
50
RoW
Eravacycline combination therapy group
Peking University Third Hospital
Pneumonitis, Acinetobacter Baumannii
10/25
10/26
NCT06666998: Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients

Not yet recruiting
N/A
100
NA
Sichuan Provincial People's Hospital
Eravacycline, Pharmacokinetics, Bacteria Infection, Bacterial Resistance to Antimicrobial, Empirical Antimicrobial Therapy
11/26
11/26
ChiCTR2400089338: The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data

Not yet recruiting
N/A
200
 
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Life Oasis Public Service Center
Granulocyte deficiency with fever
 
 
ChiCTR2400083038: A real-world study of the clinical use of eravacycline

Recruiting
N/A
50
 
None
Huashan hospital; Huashan hospital, Beijing Life Oasis public Service Center
Bacterial Infection
 
 
ChiCTR2500103344: Retrospective Study on the Efficacy and Safety of Eravacycline Based on Real-world Data

Not yet recruiting
N/A
300
 
NA
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, None
Patients clinically diagnosed with infections (including pulmonary infections, skin/soft tissue infections, intra-abdominal infections, bloodstream infections, etc.).
 
 
ChiCTR2500096976: Synergistic Mechanisms of Eravacycline Combined with Aminoglycosides in the Treatment of CRE Infections: A Single-Arm Clinical Study and Integrated Multi-Omics Analysis

Not yet recruiting
N/A
9
 
SUN YAT-SEN MEMORIAL HOSPITAL; SUN YAT-SEN MEMORIAL HOSPITAL, Primary Health Care Foundation of China
CRE infection
 
 
vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
NCT04656002: As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Not yet recruiting
2a
43
NA
Vactosertib, TEW-7197
Samsung Medical Center
Gastric Cancer
12/23
12/24
MP-VAC-206, NCT06219733: Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

Withdrawn
2
76
RoW
Vactosertib, Imatinib
MedPacto, Inc.
Dermoid
05/22
05/22
MP-VAC-205, NCT04515979: Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Terminated
2
11
RoW
Vactosertib 300 mg BID and pembrolizumab 200 mg IV, Vactosertib 300 mg BID and keytruda 200 mg IV
MedPacto, Inc.
Carcinoma, Non-Small-Cell Lung
08/24
08/24
NCT04103645: Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

Terminated
2
2
US
Vactosertib, TEW-7197
Weill Medical College of Cornell University
Myeloproliferative Neoplasm
07/24
07/24
NCT04064190: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Withdrawn
2
48
US
Vactosertib(TEW-7197)/ Durvalumab
MedPacto, Inc., AstraZeneca
Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
12/23
12/24
NCT04893252: Vactosertib and Durvalumab in Gastric Cancer

Recruiting
2
55
RoW
durvalumab and vactosertib
Hark Kyun Kim
Stomach Neoplasm
12/23
12/23
NCT03844750: Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Active, not recruiting
2
6
US
Hepatectomy, Liver Resection, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Vactosertib, EW-7197
Chloe Atreya, MD, PhD, Merck Sharp & Dohme LLC, MedPacto, Inc.
Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
04/26
04/26
NCT05436990: Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

Terminated
2
14
RoW
Pembrolizumab, Vactosertib
Yonsei University
Acral Melanoma, Mucosal Melanoma
03/25
03/25
NCT06044311: Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Recruiting
2
25
US
Vactosertib, Oral TGF-beta Receptor I Inhibitor, Standard of Care Chemotherapy, Carboplatin, Paciltaxel, Concurrent Radiation
Sakti Chakrabarti
Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
12/26
06/27
KEYNOTE 900, NCT03724851: Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer

Completed
1/2
120
RoW
TEW-7197, vactosertib
MedPacto, Inc., Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT03698825: TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer

Completed
1/2
62
RoW
TEW-7197, vactosertib
MedPacto, Inc.
Metastatic Gastric Cancer
01/22
12/22
MP-VAC-203, NCT03732274: Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

Completed
1/2
60
RoW
TEW-7197, vactosetib
MedPacto, Inc., AstraZeneca
Non-Small Cell Lung Cancer Metastatic
05/24
05/24
NCT03802084: A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor

Completed
1/2
24
RoW
vactosertib/imatinib combination
Hyo Song Kim
Desmoid Tumor
03/24
03/24
NCT05588648: Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Recruiting
1/2
48
US, RoW
Vactosertib, TEW-7197
MedPacto, Inc.
Osteosarcoma
09/25
12/25
MP-PDAC-01, NCT03666832: Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel

Recruiting
1b
36
RoW
TEW-7197, TEW-7197, FOLFOX
Joon Oh Park
Metastatic Pancreatic Cancer
12/22
12/23
NCT04258072: Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.

Recruiting
1b
24
RoW
Vactosertib, TEW-7197
Samsung Medical Center
Pancreas Cancer
12/22
03/23
CASE1A17, NCT03143985: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Completed
1
18
US
Vactosertib, TEW-7197, EW7197, EW-7197, Pomalidomide, POM
Koen van Besien
Multiple Myeloma
02/22
09/22
NCT05400122: Natural Killer (NK) Cells in Combination with Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Recruiting
1
12
US
Vactosertib, TEW-7197, EW-7197, EW7197, Fludarabine Phosphate, Fludara, Cyclophosphamide, Cytoxan, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, IL-2, Proleukin, Natural Killer Cells
David Wald
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
12/25
06/26
cynarine / Ewha Womans University, SOM Biotech
No trials found

Download Options